EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Shuai Ding, Jinfeng Liu, Xin Han, Mengfan Tang

International Journal of Molecular Sciences · 15.11.2023 · 24 (22) · 16325

DOI: 10.3390/ijms242216325 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.11.2023. Verfasst von Shuai Ding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanji…. Hauptthemen laut MEDLINE: Gene Editing, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system, an RNA-based adaptive immune system found in bacteria and archaea, has catalyzed the development and application of a new generation of gene editing tools. Numerous studies have shown that this system can precisely target a wide range of human genes, including those associated with diseases such as cancer. In cancer research, the intricate genetic mutations in tumors have promoted extensive utilization of the CRISPR/Cas9 system due to its efficient and accurate gene editing capabilities. This includes improvements in Chimeric Antigen Receptor (CAR)-T-cell therapy, the establishment of tumor models, and gene and drug target screening. Such progress has propelled the investigation of cancer molecular mechanisms and the advancement of precision medicine. However, the therapeutic potential of genome editing remains underexplored, and lingering challenges could elevate the risk of additional genetic mutations. Here, we elucidate the fundamental principles of CRISPR/Cas9 gene editing and its practical applications in tumor research. We also briefly discuss the primary challenges faced by CRISPR technology and existing solutions, intending to enhance the efficacy of this gene editing therapy and shed light on the underlying mechanisms of tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingNeoplasmsHumansCRISPR-Cas SystemsCRISPR-Associated Protein 9RNA

Stichwörter der Autor:innen

CAR-T therapyCRISPR screeningCRISPR/Cas9cancer modelgenome editing

Substanzen

CRISPR-Associated Protein 9RNA

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Department of Immunology, School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ding, S., Liu, J., Han, X., & Tang, M. (2023). CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy. International Journal of Molecular Sciences, 24(22), 16325. https://doi.org/10.3390/ijms242216325

Vancouver

Ding S, Liu J, Han X, Tang M. CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy. International Journal of Molecular Sciences. 2023;24(22):16325. doi:10.3390/ijms242216325

BibTeX
@article{Ding2023,
  author = {Ding, Shuai and Liu, Jinfeng and Han, Xin and Tang, Mengfan},
  title = {CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {22},
  pages = {16325},
  doi = {10.3390/ijms242216325}
}
Kostenlos starten →